الفرق بين النسختين بتاع: «Uğur Şahin»

ضيف لينكات
من ويكيبيديا، الموسوعه الحره
تصفح التاريخ تفاعلياً
→ التعديل اللى قبل كده
تم حذف المحتوى تمت إضافة المحتوى
مرئينص الويكي
ص تعديل و تمصير، غير: COVID-19 pandemic ← وباء كوڤيد-19، [[Katalin Karikó ← [[كاتالين كاريكو
وسم: تحويلة جديدة
 
سطر 1: سطر 1:
#تحويل [[اوغور شاهين]]
{{Short description|German oncologist and immunologist (born 1965)}}
{{Use American English|date=November 2020}}
{{Use dmy dates|date=July 2021}}
{{Infobox person
| name = Uğur Şahin
| image = Ugur Sahin v1.jpg
| caption = Şahin in 2019
| birth_date = {{Birth date and age|1965|9|19|df=y}}
| birth_place = [[İskenderun]], [[Hatay Province]], Turkey
| citizenship = Germany,<ref>{{Cite news|date=26 April 2020|title=Über zwei Wissenschaftler, die nicht nur Hoffnung gegen das Virus machen|newspaper=Der Tagesspiegel Online|url=https://www.tagesspiegel.de/gesellschaft/wir-sind-impfstoff-ueber-zwei-wissenschaftler-die-nicht-nur-hoffnung-gegen-das-virus-machen/25771136.html|access-date=2021-09-17|publisher=[[Tagesspiegel]]|language=de|quote=Beide sind Kinder türkischer Einwanderer, deutsche Staatsbürger und weltweit angesehene Wissenschaftler. ''[Both are children of Turkish immigrants, German citizens, and internationally respected scientists]''|last1=Akyün|first1=Hatice}}</ref> Turkey<ref>{{Cite web|last=United States Securities and Exchange Commission|title=SC 13G/A|url=https://www.sec.gov/Archives/edgar/data/0001776985/000119312521044856/d329239dsc13ga.htm|access-date=2022-01-03|website=sec.gov}}</ref>
| alma_mater = {{unbulleted list|[[University of Cologne|University of Cologne, Germany]]}}
| occupation = Oncologist, immunologist
| years_active = 1991–present
| known_for = {{unbulleted list|[[BioNTech]]|[[RNA vaccine]]s|[[BNT162b2]] [[vaccine]]|Personalized cancer immunotherapy}}
| office = CEO BioNTech SE
| term = 2008–present
| spouse = {{marriage|[[Özlem Türeci]]|2002}}
| children = 1
| awards = {{unbulleted list|Merit Award of the American Society of Clinical Oncology|Werner von Siemens Ring|German Cancer Award|[[Order of Merit of the Federal Republic of Germany]]|[[Mustafa Prize]] (2019)|Prix Jeantet-Collen for Translational Medicine (2022)|}}
| signature = [[File:Signature of Uğur Şahin.png|130px]]
| website = {{URL|1=https://biontech.de/de/our-dna/fuehrungsteam|2=Profile at BioNTech}}
}}

'''Uğur Şahin''' ({{IPA-tr|uˈuɾ ʃaː.hin|lang}}; born 19 September 1965<ref name=":2" />) is a German [[oncologist]] and [[immunologist]]. He is the founder and CEO of [[BioNTech]], which developed [[Pfizer–BioNTech COVID-19 vaccine|one of the major vaccines]] against [[Coronavirus disease 2019|COVID-19]].<ref name=netw>{{Cite news|url=https://www.bloomberg.com/billionaires/profiles/ugur-sahin/|title=Bloomberg Billionaires Index: Ugur Sahin |work=[[Bloomberg L.P.]] |access-date=21 June 2021 }}</ref><ref>{{cite news|author=Hatice Akyün|date=26 April 2020|title="Wir sind Impfstoff": Über zwei Wissenschaftler, die nicht nur Hoffnung gegen das Virus machen.|language=de|trans-title="We are vaccine": Two Scientists give hope, and not just against the virus|newspaper=Der Tagesspiegel|url=http://www.tagesspiegel.de/gesellschaft/wir-sind-impfstoff-ueber-zwei-wissenschaftler-die-nicht-nur-hoffnung-gegen-das-virus-machen/25771136.html|access-date=26 October 2020}}</ref> His main fields of research are [[cancer research]] and [[immunology]].<ref>{{cite news|author=Johannes Göbel|date=26 March 2015|title=Erfolgreiches "Mainzer Modell"|language=de|trans-title=Successful Mainz Model|website=Deutschland-Portal|publisher=Fazit Communication, German Federal Foreign Office|url=https://www.deutschland.de/de/topic/wissen/universitaet-forschung/erfolgreiches-mainzer-modell|access-date=26 October 2020}} The awards are to be given to them by President Frank-Walter Steinmeier at Bellevue Palace, the presidential residence on 19 March.</ref>

Şahin's family, originally from Turkey, moved to Germany when he was four years old. He grew up in [[Cologne]] and studied medicine at the [[University of Cologne]], completing a [[Doctor of Philosophy|doctoral thesis]] there in [[cancer immunotherapy]]. He initially remained in academia, in patient care as an oncohematology physician and conducting research at university hospitals in [[Saarland University|Saarland]] and [[University of Zurich|Zürich]]. He founded a research group at the [[University of Mainz]] in 2000 and became a professor of experimental [[oncology]] in 2006.

In 2001, while maintaining his position at the University of Mainz, Şahin began to engage in entrepreneurial activities, co-founding two pharmaceutical companies, in 2001 and 2008, with his partner and spouse [[Özlem Türeci]]. The second of these companies, BioNTech, together with [[Pfizer Inc]], developed one of the major vaccines used to fight the [[وباء كوڤيد-19]] in 2020. As a result of the company's increase in value, Şahin and Türeci became the first [[Turks in Germany|Germans with Turkish roots]] among Germany's 100 wealthiest people.<ref>{{cite news|author=Philip Oltermann|date=10 November 2020|title=Uğur Şahin and Özlem Türeci: German 'dream team' behind vaccine|work=The Guardian|url=https://www.theguardian.com/world/2020/nov/10/ugur-sahin-and-ozlem-tureci-german-dream-team-behind-vaccine|url-status=live|access-date=6 February 2021|archive-url=https://web.archive.org/web/20210117011752/https://www.theguardian.com/world/2020/nov/10/ugur-sahin-and-ozlem-tureci-german-dream-team-behind-vaccine|archive-date=17 January 2021|quote=The comments hinted at the scientific rigour, unrelenting work ethic and appetite for entrepreneurship that has seen Sahin and Türeci's company outpace more well-established competitors in the race for a Covid-19 vaccine – and made the couple the first Germans with Turkish roots to enter their country's rich list this autumn, at number 93.}}</ref>

== Personal life and education ==
Şahin was born on 19 September 1965<ref name=":2">{{Cite web|title=Öffentliche Bekanntmachung RegisSTAR|url=https://www.handelsregisterbekanntmachungen.de/skripte/hrb.php?rb_id=261109&land_abk=rp|access-date=2021-11-04|website=handelsregisterbekanntmachungen.de|language=de}}</ref> in [[İskenderun]] into a Turkish [[Alevi]] family.<ref>{{cite web | url = https://www.derstandard.at/story/2000122601040/migration-und-qualifikation | title = Migration und Qualifikation - derStandard.at | accessdate = 22 December 2020 | date = 18 December 2020 | language = de-AT | work = [[Der Standard]] | publisher = | first = Hans | last = Rauscher}}</ref><ref>{{cite web |last1=Tanlı |first1=Mehmet |title=Gurur ve Yanılgı |url=https://abcgazetesi.com/yazarlar/mehmet-tanli/gurur-ve-yanilgi-323052 |website=ABC |date=17 November 2020 |access-date=19 December 2021}}</ref> He moved with his mother to Germany at the age of four to join his father, who worked in [[Ford Germany|Cologne's Ford factories]].<ref>{{cite news|author=Franz Josef Wagner|date=7 October 2020|title=Betrifft: Wir sind Impfstoff.|language=de|page=18|newspaper=B.Z.|publisher=B.Z. Ullstein|issue=234}}</ref><ref>{{cite news|date=21 October 2020|title=Corona-Impfstoff könnte Biontech-Gründer Ugur Sahin weltberühmt machen.|language=de|newspaper=RTL|url=https://www.rtl.de/cms/corona-impfstoff-koennte-biontech-gruender-ugur-sahin-weltberuehmt-machen-4630380.html|access-date=26 October 2020}}</ref> He was interested in [[Association football|football]] and popular [[science book]]s, which he borrowed from the library. Initially, his primary school teacher recommended that he attend a [[hauptschule]], which would not have readily enabled him to attend university. Upon intervention of his German neighbour, he went to a [[Gymnasium (Germany)|gymnasium]] instead.<ref>{{cite web|last=Külahçı|first=Ahmet|date=18 November 2020|title='Der Retter kommt' (Kurtarıcı geliyor)|url=https://www.hurriyet.com.tr/avrupa/der-retter-kommt-kurtarici-geliyor-41665341|url-status=live|archive-url=https://web.archive.org/web/20201129195053/https://www.hurriyet.com.tr/avrupa/der-retter-kommt-kurtarici-geliyor-41665341|archive-date=29 November 2020|access-date=29 January 2021|publisher=Hürriyet}}</ref><ref>{{cite news|last1=Rossmann|first1=Ernst Dieter|last2=Samsami|first2=Behrang|date=2 December 2020|title=Gemeinsam denken|trans-title=Thinking together|url=https://www.freitag.de/autoren/behrang-samsami/gemeinsam-denken|url-status=live|archive-url=https://web.archive.org/web/20201202073731/https://www.freitag.de/autoren/behrang-samsami/gemeinsam-denken|archive-date=2 December 2020|access-date=30 January 2021|newspaper=[[Der Freitag]]}}</ref><ref>{{cite web|author=Anne Seibring|date=11 December 2020|title=Editorial|url=https://www.bpb.de/apuz/schule-2020/322678/editorial|access-date=31 January 2021|publisher=[[Federal Agency for Civic Education|Bundeszentrale für politische Bildung]]}}</ref> Taking advanced courses in mathematics and chemistry, he graduated from the Erich-Kästner-Gymnasium in [[Niehl, Cologne|Cologne-Niehl]] in 1984, and was the first child at the school with Turkish [[Foreign worker|guest worker]] parents.<ref>{{Citation|author=Bastian Ebel|title=Stolz an Kölner Schule: Irrer Lebensweg: Ex-Abiturient wird in Corona-Zeit zum Weltstar|date=11 November 2020|url=https://www.express.de/koeln/stolz-an-koelner-schule-irrer-lebensweg--ex-abiturient-wird-in-corona-zeit-zum-weltstar-37600434|trans-title=Pride at a Cologne School: Crazy Life Path: Former Student Becomes World Star in Corona Times|language=de|access-date=20 November 2020}}</ref>

Şahin met his future wife, [[Özlem Türeci]], during his work at the [[Saarland University]] Hospital (Universität des Saarlandes) in [[Homburg, Saarland|Homburg]], where Türeci completed her last year of medical studies. The couple married in 2002 and had a daughter four years later.<ref>{{Citation|author=Tobias Stolzenberg|title=Zwei gegen den Krebs|date=2018|url=https://www.heise.de/select/tr/2018/5/1525055172523270|newspaper=Technology Review|issue=5|location=Hannover|publisher=Heise Verlag|language=de|access-date=26 October 2020}}</ref><ref>{{Cite news|author=Anton Rainer|title=Biontech-Impfstoff: Wie Google eine Impf-Forscherin zur "Ehefrau" macht|url=https://www.spiegel.de/netzwelt/web/biontech-impfstoff-wie-google-eine-impf-forscherin-zur-ehefrau-macht-a-e8ace050-8329-4706-9543-8a4e3ff6cd34|access-date=11 July 2021|newspaper=Der Spiegel|date=10 November 2020|language=de}}</ref><ref>{{Cite web|date=7 December 2020|title=Özlem Türeci|url=https://www.politico.eu/list/politico-28-class-of-2021-ranking/ozlem-tureci/|access-date=11 July 2021|website=POLITICO}}</ref>

He and his wife are among the hundred richest people in Germany because of the value of their [[Shareholder|shareholding]] in BioNTech.<ref name="bi1" /> As of February 2022, ''[[Bloomberg Billionaires Index]]'' estimated his net worth at US$7.22 billion.<ref name="netw" />

=== Education ===
Şahin studied medicine at the [[University of Cologne]] from 1984 to 1992.<ref>{{cite news|last=Balzter|first=Sebastian|date=21 August 2016|title=Das Traumpaar der Biotech-Branche|language=de|trans-title=The Dream Couple of the Biotech Industry|page=27|newspaper=Frankfurter Allgemeine Sonntagszeitung|url=https://www.hmw-emissionshaus.ag/files/Pressearchiv/FAS_20160821__Traumpaar_der_Biotech_Branche.pdf|access-date=26 October 2020|via=hmw-emissionshaus.ag}}</ref><ref>{{cite web|title=Entwicklung innovativer Impfstoffe gegen Krebserkrankungen|trans-title=Development of innovative vaccines against cancer|url=https://www.youtube.com/watch?v=iHE6LsUs_bU&t=10m47s|access-date=26 October 2020|website=YouTube|at=10:47|language=de}}</ref> He received his [[doctorate]] in 1992 with a thesis on [[immunotherapy]] against [[Neoplasm|tumor cells]] (bispecific monoclonal antibodies for the activation of cytostatic precursors on tumor cells), which was graded ''[[Latin honors#Germany|summa cum laude]]''. His [[Supervisor|thesis supervisor]] was {{ill|Michael Pfreundschuh|de}}. From 1992 to 1994, he studied mathematics at the [[University of Hagen|Fernuniversität Hagen]].<ref name=":1">{{Citation|title=Prof. Dr. Ugur Sahin, Mitglied des FZI|url=https://www.fzi.uni-mainz.de/files/2019/10/CV_Prof-Sahin_aktualisiert.pdf|publisher=Forschungszentrum für Immuntherapie (FZI) der Johannes Gutenberg-Universität Mainz|access-date=26 October 2020}}</ref>

== Career ==
Şahin worked as a physician for [[internal medicine]] and [[hematology]]/oncology from 1991 to 2000 at the {{ill|University Hospital of Cologne|de|Universitätsklinikum Köln}} chaired by Volker Diehl and then at the [[Saarland University Hospital]] in [[Homburg, Saarland|Homburg]]. He [[Habilitation|habilitated]] in 1999 in the field of [[molecular medicine]] and immunology. After a one-year sabbatical with {{ill|Hans Hengartner|de|Hans Hengartner}} at the Institute for Experimental Immunology of the [[University Hospital of Zürich]] in 2000, he joined [[Christoph Huber]] at the University Medical Center Mainz. There, he has been working in various leading positions in cancer research and [[immunology]] since 2001 and has been a professor for experimental oncology at the Department for Internal Medicine/Oncohematology since 2006.<ref name=":0" /> Şahin sees himself as an immune engineer who tries to use the body's antiviral mechanisms to treat, for example, cancer, when the immune system is otherwise unable to fight it. He sees his vision in guiding the immune system is to "protect us from or alleviate certain diseases".<ref>{{Citation|author=Stefan Groß-Lobkowicz|title=Corona-Impfstoff: Für 2020 haben wir bis zu 100 Millionen Dosen geplant.|date=23 October 2020|url=https://www.theeuropean.de/stefan-gross/corona-impfstoff-fuer-2020-haben-wir-bis-zu-100-millionen-dosen-geplant/|newspaper=The European|publisher=Weimer Media Group|language=de|access-date=26 October 2020}}</ref><ref>{{Citation|author=Petra Apfel|title=Größte Hoffnung seit Jahrzehnten: Individuelle Krebsimpfung tötet Tumore.|date=9 September 2015|url=https://www.focus.de/gesundheit/ratgeber/krebs/therapie/ugur-sahin-der-tumorjaeger-aus-dem-labor-jeder-krebspatient-bekommt-sein-persoenliches-medikament_id_4767194.html|newspaper=Focus Online|language=de|access-date=26 October 2020}}</ref>

=== University Medical Center Mainz ===
In 2000, Şahin became head of the junior research group of SFB&nbsp;432 (''Sonderforschungsbereiche'', [[Collaborative Research Centers]]) of the {{ill|University Medical Center Mainz|de|Universitätsmedizin der Johannes Gutenberg-Universität Mainz}}, and in 2003 chair of the Tumor Vaccine Center.<ref name=":1" /><ref>{{Citation|title=Ugur Sahin – Biography|url=https://orcid.org/0000-0003-0363-1564|website=ORCID|access-date=26 October 2020}}</ref> From 2006 to 2013, he was Associate Professor at the Department of Experimental and Translational Oncology at the University of Mainz. Since 2014, he holds a W3 professorship at the University Medical Center of the University.

Sahin is deputy director of the University Center for Tumor Diseases Mainz (UCT Mainz), founded in 2011.<ref>{{Citation |title=Geschäftsführung |url=https://www.unimedizin-mainz.de/uct/das-uct-mainz/organisation/geschaeftsfuehrung.html |publisher=Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz) |language=de |access-date=26 October 2020}}</ref><ref>{{Citation |title=CCC-Netzwerk der Deutschen Krebshilfe – Mitglieder – Mainz |url=http://www.ccc-netzwerk.de/das-netzwerk/mitglieder/mainz.html |publisher=Stiftung Deutsche Krebshilfe |language=de |access-date=26 October 2020}}</ref> The UCT Mainz is an association of all active institutions at the University Medical Center Mainz that focus on clinical oncology or oncological research.<ref>{{Citation |title=Uni Mainz hat neues Tumor-Zentrum. |date=22 June 2011 |url=https://www.bdi.de/politik-und-presse/nachrichten/ansicht/article/uni-mainz-hat-neues-tumor-zentrum/ |publisher=Berufsverband Deutscher Internisten |language=de |access-date=26 October 2020}}</ref> In 2017, Sahin was involved in establishing the new Helmholtz Institute HI-TRON, which is a cooperation between the German Cancer Research Center (DKFZ) and TRON.<ref>{{Citation |author=Renée Dillinger-Reiter |title=Personalisierte Immuntherapie gegen Krebs |date=1 March 2017 |url=https://www.unimedizin-mainz.de/presse/pressemitteilungen/aktuellemitteilungen/newsdetail/article/personalisierte-immuntherapie-gegen-krebs.html |publisher=Universitätsmedizin Mainz |language=de |access-date=26 October 2020}}</ref><ref>{{Citation |title=Präzisionsschlag gegen den Krebs |date=14 February 2019 |url=https://www.bmbf.de/de/praezisionsschlag-gegen-den-krebs-7894.html |publisher=Bundesministerium für Bildung und Forschung (BMBF). Sieg gegen Krebs nicht unmöglich. |language=de |access-date=26 October 2020}}</ref><ref>{{Citation |title=Helmholtz-Institut für Translationale Onkologie Mainz |url=https://www.dkfz.de/de/hi-tron/index.html |publisher=Deutsches Krebsforschungszentrum |language=de |access-date=26 October 2020}}</ref> A project that Sahin led at the University Medical Center for developing innovative vaccines against cancer was one of twelve projects awarded a sponsorship prize by the German Federal Ministry of Education and Research in 2006 as part of the newly created biotechnology start-up offensive (GO-Bio).

;Translational Oncology at the University Medical Center (TRON)
In 2010, he co-founded TRON (Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz). TRON is a non-profit (private) [[biopharmaceutical]] [[research institute]] that develops new [[Diagnosis|diagnostic tools]] and drugs to treat cancer and other diseases with a high unmet medical need.<ref>{{Citation|title=Über TRON|url=https://tron-mainz.de/de/ueber-tron/|publisher=TRON – Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz|language=de|access-date=26 October 2020}}</ref> Its focus is on individualized medicine and cancer immunotherapy. For his work in this field, Şahin was awarded the {{ill|German Cancer Prize|de|Deutscher Krebspreis}}.<ref>{{Citation|author=Petra Spielberg|title=Ugur Sahin: Mit individualisierten Therapien gegen den Krebs.|date=2019|url=https://www.aerzteblatt.de/archiv/207247/Ugur-Sahin-Mit-individualisierten-Therapien-gegen-den-Krebs|newspaper=Deutsches Ärzteblatt|issue=116|language=de|access-date=26 October 2020}}</ref><ref>{{Citation|author=Renée Dillinger-Reiter|title=Professor Ugur Sahin erhält den Deutschen Krebspreis 2019|date=28 February 2019|url=https://www.unimedizin-mainz.de/presse/pressemitteilungen/aktuellemitteilungen/newsdetail/article/professor-ugur-sahin-erhaelt-den-deutschen-krebspreis-2019.html|publisher=Universitätsmedizin Mainz|language=de|access-date=26 October 2020}}</ref>

From its foundation until September 2019, he was TRON's scientific director.<ref>{{Citation|title=Management|url=https://tron-mainz.de/de/ueber-tron/management/|publisher=TRON – Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz|language=de|access-date=26 October 2020}}</ref> Since then, he has been working as a scientific advisor and supervisor of [[Doctor of Philosophy|Ph.D.]] students.<ref name="TRON">{{Citation|title=Neues Spitzenforschungsinstitut in Mainz: TRON – Translationale Onkologie. Bindeglied zwischen Universität, Universitätsmedizin und Wirtschaft.|date=18 February 2010|url=http://www.uni-mainz.de/presse/35054.php|publisher=Ministerium für Wissenschaft, Weiterbildung und Kultur des Landes Rheinland-Pfalz|access-date=26 October 2020}}</ref>

;Helmholtz Institute (HI-TRON)
He is one of the scientific directors of the new Helmholtz Institute.<ref>{{Citation|title=Neues Helmholtz-Institut|date=14 February 2019|url=https://www.welt.de/regionales/rheinland-pfalz-saarland/article188764059/Sieg-gegen-Krebs-nicht-unmoeglich-neues-Helmholtz-Institut.html|newspaper=Die Welt|language=de|access-date=26 October 2020}}</ref> During the founding ceremony, Şahin declared that he believes "cancer can be defeated in the future".<ref>{{Citation|title=Experte für Immuntherapie: Sieg gegen Krebs nicht unmöglich.|url=https://www.faz.net/1.6041022|newspaper=Frankfurter Allgemeine Zeitung|date=14 February 2019 |language=de|issn=0174-4909|access-date=26 October 2020}}</ref>

=== Ganymed Pharmaceuticals ===
Şahin co-founded the company Ganymed Pharmaceuticals in 2001 with his wife Özlem Türeci and his mentor Christoph Huber.<ref>{{Citation|author=Joe Miller|title=Ugur Sahin: The Immunologist Racing To Find a Vaccine|date=20 March 2020|url=https://www.ft.com/content/36ddd384-6abf-11ea-a3c9-1fe6fedcca75|newspaper=Financial Times|access-date=26 October 2020}}</ref> Ganymed developed the [[monoclonal antibody]] [[Zolbetuximab]], for use against esophageal and gastrointestinal cancer.<ref>{{Citation|author=Tobias Stolzenberg|title=Zwei gegen den Krebs|date=8 October 2018|url=https://www.heise.de/hintergrund/Zwei-gegen-den-Krebs-4129169.html|newspaper=Heise Online|language=de|access-date=26 October 2020}}</ref> In 2016, after showing in a randomized clinical trial that this drug significantly boosted advanced gastric cancer patients' overall survival,<ref>{{Cite web|title=This Obscure Biotech May Have a Game-Changing Cancer Med On Its Hands|url=https://fortune.com/2016/06/06/asco-ganymed-gastric-cancer-med/|access-date=30 June 2021|website=Fortune}}</ref> the company was sold to [[Astellas Pharma]] for over {{euro}}400&nbsp;million.<ref>{{Citation|title=Astellas kauft Ganymed|date=28 October 2016|url=https://transkript.de/news/astellas-kauft-ganymed.html|newspaper=Transkript|language=de|access-date=26 October 2020}}</ref> The drug is in Phase&nbsp;III trials as of 2020.<ref>{{Cite Q|Q93031588}}</ref><ref>{{Citation|title=Antibody Shines in Advanced Gastric Cancer|date=5 June 2016|url=https://www.medpagetoday.com/meetingcoverage/asco/58317|access-date=26 October 2020}}</ref><ref>{{Citation|title=A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|url=https://clinicaltrials.gov/ct2/show/NCT03653507|website=ClinicalTrials|publisher=U.S. National Library of Medicine|access-date=26 October 2020}}</ref>

=== BioNTech ===
[[File:Mainz.BioNTechSE.20200731.jpg|thumb|Headquarters of BioNTech SE in Mainz, Germany]]
Together with Özlem Türeci and Christoph Huber, Şahin founded the biotechnology company [[BioNTech]], based in Mainz, Germany, in 2008 and serves as its [[Chief executive officer|CEO]].<ref>{{Citation|title=Ministerpräsidentin Malu Dreyer sagt Mainzer Impfstoffentwickler BioNTech Unterstützung zu.|date=15 May 2020|url=https://www.rlp.de/de/aktuelles/einzelansicht/news/News/detail/ministerpraesidentin-malu-dreyer-sagt-mainzer-impfstoffentwickler-biontech-unterstuetzung-zu/|publisher=Staatskanzlei Rheinland-Pfalz|language=de|access-date=26 October 2020}}</ref><ref>{{Citation|title=Ugur Sahin, Profile and Biography|url=https://www.bloomberg.com/profile/person/18869003|website=Bloomberg|access-date=26 October 2020}}</ref> BioNTech is focused on developing and manufacturing active [[Immunotherapy|immunotherapies]] for a patient-specific approach to the treatment of cancer and other serious diseases.<ref>{{Citation|last1=Hofmann|first1=Siegfried|title=Impfung gegen Krebs|date=16 March 2016|newspaper=Handelsblatt|page=16|language=de|last2=Terpitz|first2=Katrin}}</ref> The main focus of his research work is the discovery of mRNA-based drugs for use as individualized cancer immunotherapies, as vaccines against infectious diseases, and as protein replacement therapies for rare diseases.<ref>{{Citation|author=Kutter, Susanne|title=Der große Schlag im Kampf gegen den Krebs|date=3 June 2016|newspaper=WirtschaftsWoche|issue=23|page=14|language=de}}</ref> He holds a minority interest in the listed company.<ref>{{Citation|title=BioNTech-Aktie|url=https://www.finanzen.net/aktien/biontech-aktie|website=finanzen.net|language=de|access-date=26 October 2020}}</ref><ref>{{Citation|author=Wolfram Weimer|title=Der Impfstoff naht|date=13 October 2020|url=https://www.n-tv.de/politik/politik_person_der_woche/Der-Impfstoff-naht-article22095146.html|website=n-tv|language=de|access-date=26 October 2020}}</ref> Since April&nbsp;2020, BioNTech has been researching a vaccine for the disease [[Coronavirus disease 2019|COVID-19]] under Şahin and Türeci, who is also a member of the company's [[board of directors]].<ref>{{Citation|author=Siegfried Hofmann, Christian Wermke|title=Ugur Sahin und Özlem Türeci: Dieses Medizinerpaar entwickelt einen Covid-19-Impfstoff.|date=23 April 2020|url=https://www.handelsblatt.com/unternehmen/industrie/ugur-sahin-und-oezlem-tuereci-dieses-medizinerpaar-entwickelt-einen-covid-19-impfstoff/25766452.html|newspaper=Handelsblatt|language=de|access-date=26 October 2020}}</ref><ref>{{cite news|last=Gelles|first=David|date=10 November 2020|title=The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19|website=The New York Times|url=https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html|access-date=17 November 2020}}</ref> Şahin is involved in several [[patent]]s that he has filed with his company and partners.

Against the background of the debate about the distribution of a potential vaccine, Şahin stated that one key in the fight against COVID-19 is international cooperation and equality of distribution. He said there was "no discussion" about whether a vaccine would be made available exclusively to individual countries.<ref>{{Citation|last1=Kopplin|first1=Ilka|title=Mainzer Unternehmen: Wie Biontech gegen Corona kämpft.|date=16 March 2020|url=https://www.faz.net/aktuell/wirtschaft/unternehmen/mainzer-unternehmen-wie-biontech-gegen-corona-kaempft-16682001.html|newspaper=Frankfurter Allgemeine Zeitung|language=de|access-date=26 October 2020|last2=Schleidt|first2=Daniel}}</ref><ref>{{Citation|author=Salz, Jürgen|title=Biontech-Chef Ugur Sahin: 'Wir wollen keine Abkürzung gehen.'|date=8 September 2020|url=https://www.wiwo.de/unternehmen/industrie/biontech-chef-ugur-sahin-wir-wollen-keine-abkuerzung-gehen/26168404.html|newspaper=WirtschaftsWoche|language=de|access-date=26 October 2020}}</ref> Şahin opposes compulsory vaccination and emphasizes the voluntary nature of the vaccination.<ref>{{cite web |last1=Döpfner |first1=Mathias |title=INTERVIEW: BioNTech founders Özlem Türeci and Ugur Sahin on developing the BioNTech-Pfizer COVID-19 vaccine, the future of fighting cancer, and whether people can live to 200 |url=https://www.businessinsider.com/pfizer-biontech-vaccine-creators-science-covid-19-dose-health-2021-3? |website=Business Insider |date=23 March 2021}}</ref>

In fall 2020, he entered a partnership with the U.S. pharmaceutical company Pfizer and planned to obtain approval for a vaccine before the end of 2020.<ref>{{Citation|author=Paul R. La Monica|title=Pfizer May File for Early COVID-19 Vaccine Use – but Not Until After the Election|date=16 October 2020|url=https://www.cnn.com/2020/10/16/investing/pfizer-vaccine-emergency-use-authorization/index.html|newspaper=CNN Business|publisher=Cable News Network, A Warner Media Company|access-date=26 October 2020}}</ref><ref>{{Citation|author=Bojan Pancevski, Jared S. Hopkins|title=How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race. Small German Biotech Was a Niche Player in Futuristic Cancer Treatments—Then Pivoted When COVID-19 Broke Out in China.|date=22 October 2020|url=https://www.wsj.com/articles/how-pfizer-partner-biontech-became-a-leader-in-coronavirus-vaccine-race-11603359015|newspaper=The Wall Street Journal|publisher=Dow Jones & Company|issn=0099-9660|access-date=26 October 2020}}</ref><ref>{{Citation|author=Jürgen Salz, Silke Wettach|title=Nach zähen Verhandlungen: EU kauft Millionen Dosen Impfstoff bei Biontech und Pfizer ein.|date=9 September 2020|url=https://www.wiwo.de/my/unternehmen/industrie/nach-zaehen-verhandlungen-eu-kauft-millionen-dosen-impfstoff-bei-biontech-und-pfizer-ein/26164670.html|newspaper=WirtschaftsWoche|language=de|access-date=26 October 2020}}</ref> In November, the company reported a 95 percent efficacy of the [[BNT162b2]] vaccine.<ref>{{Citation|author=heise online|title=Biontech/Pfizer-Corona-Impfstoff: 95 Prozent Wirksamkeit nach Phase-3-Auswertung|date=19 November 2020 |url=https://www.heise.de/news/Biontech-Pfizer-Corona-Impfstoff-95-Prozent-Wirksamkeit-nach-Phase-3-Auswertung-4965389.html|language=de|access-date=24 November 2020}}</ref>

== Research ==
{{Overly detailed|section|details=|date=October 2021}}
Şahin has worked with Türeci as a physician-scientist couple since they met in 1992. Their early work focussed on identifying and characterizing new target molecules (antigens) for the immunotherapy of cancer. They discovered tumor antigens relevant for treatment of various types of cancers, e.g. [[stomach cancer]], [[pancreatic cancer]], [[breast cancer]], [[ovarian cancer]], [[prostate cancer]], [[lung cancer]] and other dangerous cancers.<ref>{{Cite Q|Q92379967|doi-access=free}}</ref><ref>{{Cite Q|Q45401730|doi-access=free}}</ref><ref>{{Cite Q|Q30854839}}</ref>

Şahin and his team established strategies that allow different layers of mRNA vaccine optimization, including optimizations of the various structural backbone elements of mRNA molecules, ways to utilize uridine-based as well as nucleoside-modified mRNA chemistries, and different lipid-based compositions and administration routes to deliver mRNA. Systematically combining mRNA modifications achieved an exponential improvement in the potency of mRNA vaccines and its adaption to various purposes.<ref name="ReferenceA">{{Cite Q|Q54585198}}</ref><ref>{{Cite Q|Q57221515|doi-access=free}}</ref><ref>{{Cite Q|Q45858586|doi-access=free}}</ref><ref>{{Cite Q|Q38252360|doi-access=free}}</ref><ref>{{Citation|title=mRNA therapeutics in cancer immunotherapy|year=2021|pmid=33858437|last1=Beck|first1=J. D.|last2=Reidenbach|first2=D.|last3=Salomon|first3=N.|last4=Sahin|first4=U.|last5=Vormehr|first5=M.|last6=Kranz|first6=L. M.|journal=Molecular Cancer|volume=20|issue=1|page=69|doi=10.1186/s12943-021-01348-0|pmc=8047518 |doi-access=free }}</ref> Building on this toolbox of improvements of RNA molecules, Şahin successfully used mRNA for applications in humans.

===RNA vaccines targeting individual cancer mutations===

One application Sahin's team pioneered are mRNA vaccines for personalized [[Cancer|cancer therapy]] that are based on non-nucleoside modified mRNA. This technology relies on targeting tumor-specific mutations that are not present in normal cells. Each patient's tumor has a unique set of mutations. Since mRNA vaccines can be easily designed to target any antigen, the team could use the mutation fingerprint of cancers for engineering mRNA-based personalized neo-antigen vaccines. This application offers the possibility of targeting each patient's tumor mutations with an individually tailored mRNA vaccine of unique composition that is produced "on demand".

===RNA vaccines targeting tumor-associated antigens===

To apply their RNA cancer vaccine to tumor-associated antigens (TAAs) shared between patients, Sahin and his team developed RNA vaccine nanoparticle delivery strategies that target tissue-derived dendritic cells body-wide. They pioneered the first intravenous nanoparticle delivery of mRNA vaccines in humans. They observed strong tumor-antigen-specific immune responses induced by their uridine-based non-nucleoside modified mRNA vaccines, even though the utilized TAAs are self-antigens. This was a critical step toward the development of effective, potent cancer vaccines targeting a broad range of antigens for [[immunotherapy]].

===RNA vaccines to improve CAR-T therapy===

Chimeric [[antigen]] [[Receptor (biochemistry)|receptor]] (CAR)-T cell therapies (CARVAC) are promising immunotherapies for treating B-cell-derived hematologic cancers. Achieving long-term patient responses in solid tumors remains a challenge due to poor activity of CAR-T cells against solid cancer. Sahin and his team have developed ways to use RNA vaccine technology for [[in vivo]] expansion and enhanced engraftment of genetically engineered, adoptively transferred CAR-T cells. This has been effective in inducing regression of large tumors in challenging mouse cancer models. The approach is now in clinical trials for the treatment of patients with various cancers.

===RNA vaccines to induce antigen-specific tolerance in autoimmune disease===
[[File:Empfang für Özlem Türeci und Uğur Şahin im Rathaus Köln-5356.jpg|thumb|Şahin and his wife [[Özlem Türeci]] during the honorary doctorate ceremony given by the [[University of Cologne]] Faculty of Medicine, 2021]]
[[Autoimmunity|Autoimmune]] diseases, such as [[multiple sclerosis]] (MS), result from tissue damage caused by self-reactive T [[lymphocyte]]s. Combating autoimmune diseases is challenging and can lead to systemic immunosuppression and side effects such as increased risk of infection. Şahin and his team developed a novel therapeutic strategy that circumvents systemic immunosuppression by inhibiting only the immune cells that mediate [[autoimmune disease]]. They used a different version of [[Solid lipid nanoparticle|lipid nanoparticles]] to deliver MS [[Autoimmunity|autoantigens]] encoded by a non-inflammatory RNA into [[dendritic cell]]s. This approach expands a specific type of immune cells, called antigen-specific regulatory effector [[T cell]]s, which suppress autoreactivity against the targeted autoantigens and also promote inhibition of [[Reactive lymphocyte|autoreactive T cells]] against other [[myelin]]-specific autoantigens. The [[MRNA vaccine|RNA vaccine]] used for tolerance induction contained [[N1-Methylpseudouridine|1-methylpseudouridine]] (m1Ψ) instead of uridine, a modification previously described by [[كاتالين كاريكو]] and colleagues that does not stimulate [[Toll-like receptor]]s. In mouse models of MS, the novel RNA vaccine approach delayed onset and reduced severity of established disease without inducing generalized [[immunosuppression]].<ref>{{Cite Q|Q104766936}}</ref><ref>{{Citation|title=mRNA vaccine shows promise in autoimmunity|year=2021|pmid=33437044|last1=Flemming|first1=A.|journal=Nature Reviews. Immunology|volume=21|issue=2|page=72|doi=10.1038/s41577-021-00504-3|pmc=7802056}}</ref><ref>{{Citation|title=mRNA vaccines take on immune tolerance|year=2021|pmid=33785909|last1=Wardell|first1=C. M.|last2=Levings|first2=M. K.|journal=Nature Biotechnology|volume=39|issue=4|pages=419–421|doi=10.1038/s41587-021-00880-0|s2cid=232431542|doi-access=free}}</ref>

===RNA vaccine against COVID-19===

In January 2020, Sahin and his teams pivoted from cancer to COVID-19 vaccine development. The rapid publication of the [[sequence]] of SARS-COV-2 enabled them to initiate an RNA vaccine discovery program. The versatile nature of their mRNA technology and the groundwork Sahin's team had done in the area of cancer vaccines allowed them to develop, produce and test multiple mRNA vaccine candidates in parallel. [[Pfizer–BioNTech COVID-19 vaccine|BNT162b2]] was discovered as the best{{according to whom|date=October 2021}} candidate for the particular purpose of vaccinating for COVID19 prevention. BNT162b2 is a [[lipid]] [[nanoparticle]] encapsulated, nucleoside-modified RNA vaccine encoding SARS-CoV-2 [[coronavirus spike protein|spike protein]] and combines multiple features for optimized vaccine activity derived from Sahin, Türeci and their teams prior work.<ref name="ReferenceA"/><ref>{{Cite web|last=|first=|title=Corona-Impfung erklärt: So funktioniert der programmierbare BioNTech-Impfstoff|url=https://www.heise.de/hintergrund/Corona-Impfung-erklaert-So-funktioniert-der-programmierbare-BioNTech-Impfstoff-5060246.html|access-date=30 June 2021|website=c't Magazin|date=23 February 2021|language=de}}</ref><ref>{{Cite Q|Q91028225}}</ref> [[Clinical trial]]s and subsequent real-world studies established that BNT162b2 vaccine is very effective in inducing immune responses and proved the safety and potent efficacy in humans.<ref>{{Citation|title=BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans|year=2021|pmid=34044428|last1=Sahin|first1=U.|last2=Muik|first2=A.|last3=Vogler|first3=I.|last4=Derhovanessian|first4=E.|last5=Kranz|first5=L. M.|last6=Vormehr|first6=M.|last7=Quandt|first7=J.|last8=Bidmon|first8=N.|last9=Ulges|first9=A.|last10=Baum|first10=A.|last11=Pascal|first11=K. E.|last12=Maurus|first12=D.|last13=Brachtendorf|first13=S.|last14=Lörks|first14=V.|last15=Sikorski|first15=J.|last16=Koch|first16=P.|last17=Hilker|first17=R.|last18=Becker|first18=D.|last19=Eller|first19=A. K.|last20=Grützner|first20=J.|last21=Tonigold|first21=M.|last22=Boesler|first22=C.|last23=Rosenbaum|first23=C.|last24=Heesen|first24=L.|last25=Kühnle|first25=M. C.|last26=Poran|first26=A.|last27=Dong|first27=J. Z.|last28=Luxemburger|first28=U.|last29=Kemmer-Brück|first29=A.|last30=Langer|first30=D.|journal=Nature|volume=595|issue=7868|pages=572–577|doi=10.1038/s41586-021-03653-6|bibcode=2021Natur.595..572S|s2cid=235232604|display-authors=1|doi-access=free}}</ref><ref>{{Citation|title=BNT162b vaccines protect rhesus macaques from SARS-CoV-2|year=2021|pmid=33524990|last1=Vogel|first1=A. B.|last2=Kanevsky|first2=I.|last3=Che|first3=Y.|last4=Swanson|first4=K. A.|last5=Muik|first5=A.|last6=Vormehr|first6=M.|last7=Kranz|first7=L. M.|last8=Walzer|first8=K. C.|last9=Hein|first9=S.|last10=Güler|first10=A.|last11=Loschko|first11=J.|last12=Maddur|first12=M. S.|last13=Ota-Setlik|first13=A.|last14=Tompkins|first14=K.|last15=Cole|first15=J.|last16=Lui|first16=B. G.|last17=Ziegenhals|first17=T.|last18=Plaschke|first18=A.|last19=Eisel|first19=D.|last20=Dany|first20=S. C.|last21=Fesser|first21=S.|last22=Erbar|first22=S.|last23=Bates|first23=F.|last24=Schneider|first24=D.|last25=Jesionek|first25=B.|last26=Sänger|first26=B.|last27=Wallisch|first27=A. K.|last28=Feuchter|first28=Y.|last29=Junginger|first29=H.|last30=Krumm|first30=S. A.|journal=Nature|volume=592|issue=7853|pages=283–289|doi=10.1038/s41586-021-03275-y|bibcode=2021Natur.592..283V|s2cid=231756922|display-authors=1|doi-access=free}}</ref><ref>{{Cite Q|Q104265015}}</ref> BNT162b2 became the first mRNA drug approved for human use and the fastest vaccine developed against a new pathogen in the history of medicine.<ref>{{Cite Q|Q104503055}}</ref>

== Memberships ==
[[File:Ugur Sahin 01.jpg|thumb|Şahin in 2019]]
Şahin has been a member of the {{ill|German Society of Immunology|de|Deutsche Gesellschaft für Immunologie}} since 2004 and a member of the Program Committee of the Association for Cancer Immunotherapy (CIMT), Regulatory Research Group, Mainz, since 2008. In 2012, he was among the founders of the Cluster of Individualized Immunointervention (CI3) in Mainz.<ref>{{Citation|title=The Cluster for Individualized Immune Intervention (Ci3)|url=https://ci-3.de/whoweare/|access-date=26 October 2020}}</ref><ref>{{Citation|title=Cluster für Individualisierte ImmunIntervention (Ci3) – BMBF Spitzencluster|url=https://www.spitzencluster.de/de/cluster-fuer-individualisierte-immunintervention-ci3-1718.html|publisher=Bundesministerium für Bildung und Forschung (BMBF)|language=de|access-date=26 October 2020}}</ref> He has been a member of the [[American Association for Cancer Research]] (AACR) since 2014 and of the [[American Society of Clinical Oncology]] (ASCO) since 2015.<ref name=":0" /> In 2021 Sahin was elected as a member of the [[European Molecular Biology Organization]] (EMBO).

== Publications (selection) ==
The [[United States National Library of Medicine|U.S. National Library of Medicine]] lists 345 clinical studies and other publications in which Şahin was involved; he is first author of 49.<ref>{{Citation|title=Advanced Search|url=https://clinicaltrials.gov/ct2/search/advanced|website=ClinicalTrials|publisher=U.S. National Library of Medicine|access-date=25 November 2020}}</ref> The [[United States Patent and Trademark Office|U.S. Patent and Trademark Office]] lists several patents related to him.<ref>{{Citation|title=Advanced Search|url=http://patft.uspto.gov/netahtml/PTO/search-adv.htm|website=Patent Full-Text and Image Database|publisher=U.S. Patent and Trademark Office|access-date=25 November 2020}}</ref>

Based on the top-cited patent over the past five years, and H-index, a calculation of the impact of a researcher's publications over time, Sahin was ranked in [[Nature (journal)|Nature]] Biotechnology's Top 20 translational researchers in the years of 2015,<ref>{{Cite journal|title=Table 1 Top 20 translational researchers in 2015|journal=Nature Biotechnology|url=https://www.nature.com/articles/nbt.3686/tables/1|issn=1546-1696}}</ref> 2018 and 2019.<ref>{{Cite Q|Q91657804}}</ref>

; Selection
* {{Cite Q|Q57221515}}
* {{Cite Q|Q45867833}}
* {{Cite Q|Q39413641}}
* {{Cite Q|Q57221424}}
* {{Cite Q|Q38252360}}<!-- Previous citation gave "mRNA-based therapeutics–developing a new class of drugs" which is Q38252360 -->
* {{Cite Q|Q34249684}}<!-- Previous citation gave doi:10.1093/nar/gku757, PMC 4176373, PMID 25150148, which is Q34249684 -->
* {{Cite Q|Q48649314}}
* {{Cite Q|Q36817092}}
* {{Cite Q|Q28005535}}
* {{Cite Q|Q50949304}}
* {{Cite Q|Q50906889}}
* {{Cite Q|Q52641910}}
* {{Cite Q|Q104265015}}
* {{cite book |last1=Miller |first1=Joe |last2=Şahin |first2=Uğur |last3=Türeci | first3=Özlem |author-link3=Özlem Türeci |date=2021 |title=Projekt Lightspeed: Der Weg zum BioNTech-Impfstoff |trans-title=Project Lightspeed: The Road to the [[Pfizer–BioNTech COVID-19 vaccine|BioNTech Vaccine]] |url= |url-status= |url-access= |format= |language=de |location=Hamburg |publisher=[[Rowohlt Verlag]] |isbn=978-3-498-00277-0 |pages=352 |edition=1st}}

== Awards (selection) ==

* 1995: Vincenz Czerny Prize of the {{ill|German Society of Hematology and Oncology (DGHO)|de|Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie}}<ref>{{Citation|title=Preisträger Vincenz-Czerny-Preis und deren Arbeiten|url=https://www.dgho.de/aktuelles/preisausschreiben/vincenz-czerny-preis/preistraeger-vincenz-czerny-preis-und-deren-arbeiten|publisher=Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie|language=de|access-date=26 October 2020}}</ref>
* 1995: Merit Award of the [[American Society of Clinical Oncology]] (ASCO)<ref name=":0">{{Citation|title=Prof. Dr. med. Ugur Sahin|url=https://www.sfb1399.de/research/principal-investigators/prof-dr-med-ugur-sahin|website=SFB 1399: Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer|publisher=Department of Translational Genomics, University of Cologne|access-date=26 October 2020}}</ref>
* 1997: Calogero Paglierello Research Award<ref>{{Citation|title=Ugur Sahin, Managing Director (Science and Research) of Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz – Tron|url=https://www.birmingham.ac.uk/schools/cancer/events/spring-2015/Dr-Professor-Ugur-Sahin.aspx|publisher=University of Birmingham|access-date=26 October 2020}}</ref>
* 2005: {{ill|Georges Köhler Prize|de|Georges-Köhler-Preis}} of the {{ill|German Society of Immunology|de|Deutsche Gesellschaft für Immunologie}}<ref>{{Citation|title=Erfolgreiche Suche nach Tumormarkern|date=13 October 2005|url=https://www.aerztezeitung.de/Medizin/Erfolgreiche-Suche-nach-Tumormarkern-376780.html|newspaper=Ärzte Zeitung|publisher=Springer Medizin|language=de|access-date=26 October 2020}}</ref><ref>{{Citation|title=Koehler-Preis|date=20 June 2018|url=https://dgfi.org/preise/koehler-preis/|publisher=Deutsche Gesellschaft für Immunologie|language=de|access-date=26 October 2020}}</ref>
* 2006 and 2010: GO-Bio Prize of the [[Federal Ministry of Education and Research (Germany)|Federal Ministry of Education and Research]]<ref>{{Citation|title=GO-Bio Erfolge|url=https://go-bio.de/de/erfolge-1713.html|publisher=Bundesministerium für Bildung und Forschung (BMBF)|language=de|access-date=26 October 2020}}</ref>
* 2012: BMBF Spitzencluster Award for TRON projects as part of CI3-Regional Cluster for Individualized Immune Intervention<ref>{{Citation|title=Prof. Ugur Sahin, MD PhD|url=http://iscoms.com/prof-mario-r-capecchi-phd-2/|website=ISCOMS|publisher=International Student Congress of (Bio)medical Sciences|access-date=26 October 2020}}</ref>
* 2017/18: ERC Advanced Grant in Life Sciences<ref>{{Citation|title=Prof. Ugur Sahin Receives Prestigious European Research Council (ERC) Advanced Grant for Personalized Cancer Vaccines|date=19 April 2018|url=https://www.wissenschaftsallianz-mainz.de/en/news-detail/prof-ugur-sahin-receives-prestigious-european-research-council-erc-advanced-grant-for-personalize/|publisher=Mainzer Wissenschaftsallianz|language=de|access-date=26 October 2020}}</ref>
* 2019: [[Mustafa Prize]]<ref>{{Citation|title=The 2019 Mustafa Prize Laureates|url=https://www.mustafaprize.org/laureates2019|access-date=26 October 2020}}</ref>
* 2019: {{ill|German Cancer Award|de|Deutscher Krebspreis}}<ref>{{Citation|title=Viermal Deutscher Krebspreis für DKTK Wissenschaftler|date=28 February 2019|url=https://dktk.dkfz.de/de/ueber-uns/news/viermal-deutscher-krebspreis-fuer-dktk-wissenschaftler|publisher=Deutsches Konsortium für Translationale Krebsforschung (DKTK) – Deutsches Krebsforschungszentrum|language=de|access-date=26 October 2020}}</ref>
* 2020: [[The National German Sustainability Award]]<ref name="Deutscher Nachhaltigkeitspreis">{{Cite web|title=Deutscher Nachhaltigkeitspreis: Startseite|url=https://www.nachhaltigkeitspreis.de/|access-date=17 December 2020|website=Deutscher Nachhaltigkeitspreis|language=de}}</ref>
* 2020: [[Financial Times Person of the Year]]<ref name="Miller Cookson 2020">{{Cite news|last1=Miller|first1=Joe|last2=Cookson|first2=Clive|date=16 December 2020|title=FT People of the Year: BioNTech's Ugur Sahin and Ozlem Tureci|url=https://www.ft.com/content/6633221e-3b28-4a15-b02d-958854644c79|access-date=17 December 2020|website=Financial Times}}</ref>
* 2021: Knight Commander's Cross of the [[Order of Merit of the Federal Republic of Germany]]<ref>{{cite web|last1=Hessler|first1=Uwe|last2=Wrede|first2=Insa|title=BioNTech vaccine inventors receive Germany's Knight Commander's Cross {{!}} DW {{!}} 19 March 2021|url=https://www.dw.com/en/biontech-vaccine-inventors-receive-germanys-knight-commanders-cross/a-56912141|website=DW.COM}}</ref><ref>{{Cite web|title=Bundespräsident ehrt Özlem Türeci und Uğur Şahin mit Verdienstorden|trans-title=Federal President honors Özlem Türeci and Uğur Şahin with Order of Merit|url=https://www.bundespraesident.de/SharedDocs/Pressemitteilungen/DE/2021/02/210226-OV-Tuereci-Sahin.html|access-date=30 June 2021|website=bundespraesident.de|language=de}}</ref>
* 2021: Hall of Fame German Science<ref>{{Cite web|title=HoF - Hall of Fame (Laureates)|url=https://www.emdgroup.com/en/hall-of-fame-der-deutschen-forschung/hall-of-fame.html|access-date=30 June 2021|website=emdgroup.com}}</ref>
* 2021: Empress Theophano Prize<ref>{{Cite web|title=Theophano Foundation – Prize 2021|url=https://www.theophano.eu/winners-2021/|access-date=30 June 2021|website=theophano.eu}}</ref>
* 2021: Election as a Member of EMBO<ref>{{Cite web|title=EMBO announces 64 newly elected members – Press releases – EMBO|date=8 June 2021 |url=https://www.embo.org/press-releases/embo-announces-64-newly-elected-members/|access-date=30 June 2021}}</ref>
*2021: [[Karl Heinz Beckurts]] Prize<ref>{{Cite web|title=DESY News: Karl Heinz Beckurts Prize awarded at DESY|url=https://www.desy.de/news/news_search/index_eng.html?openDirectAnchor=2176&two_columns=0|access-date=2021-11-16|website=www.desy.de|language=en}}</ref>
* 2021: [[Princess of Asturias Awards|Princess of Asturias Award]] in the category "Scientific Research"<ref>[https://www.fpa.es/en/princess-of-asturias-awards/laureates/2021-katalin-kariko-drew-weissman-philip-felgner-ugur-sahin-ozlem-tureci-derrick-rossi-and-sarah-gilbert.html?especifica=0&idCategoria=0&anio=2021&especifica=0 Princess of Asturias Award 2021]</ref>
* 2021: [[William B. Coley Award]]<ref>{{Cite web|title=William B. Coley Award|url=https://www.cancerresearch.org/en-us/about-cri/awards-honors/william-b-coley-award|access-date=2021-11-16|website=Cancer Research Institute|language=en}}</ref>
* 2021: [[Society for Immunotherapy of Cancer|SITC]] Medal of Honor<ref>{{Cite web|title=SITC Medal of Honor - Society for Immunotherapy of Cancer (SITC)|url=https://www.sitcancer.org/funding/awards/medal-of-honor|access-date=2021-11-16|website=www.sitcancer.org}}</ref>
* 2021: [[German Future Prize]]<ref>{{Cite news|title=Impfstoff-Entwickler von Biontech erhalten Zukunftspreis|url=https://www.forschung-und-lehre.de/forschung/impfstoffentwickler-von-biontech-erhalten-zukunftspreis-4191|date=2021-11-17|access-date=2021-11-17|work=Forschung & Lehre|language=de}}</ref>
*2021: Empress Theophano Prize <ref>{{Cite news|title=The Empress Theophano Prize Honours the Contribution of Science to Humankind|url=https://www.theophano.eu/winners-2021}}</ref>
* 2022: [[Paul Ehrlich and Ludwig Darmstaedter Prize]], Germany's most prestigious medical award, received at [[St. Paul's Church, Frankfurt am Main]]<ref>{{cite web | url=https://www.dw.com/en/biontech-founders-win-german-medicine-prize/a-59243208 | title=BioNTech founders win top German medicine award &#124; DW &#124; 21.09.2021 | website=[[Deutsche Welle]] }}</ref><ref>[https://nachrichten.idw-online.de/2021/09/21/katalin-kariko-oezlem-tuereci-und-ugur-sahin-erhalten-paul-ehrlich-und-ludwig-darmstaedter-preis-2022/ Paul Ehrlich and Ludwig Darmstaedter Prize]</ref>
* 2022: Honorary doctorate of the [[University of Marburg|Philipps University of Marburg]] (together with Özlem Türeci)<ref>{{Cite web |title=Ehrendoktorwürde für Özlem Türeci und Uğur Şahin |url=https://www.uni-marburg.de/de/aktuelles/news/2021/ehrendoktorwuerde-fuer-oezlem-tuereci-und-ugur-sahin |access-date=2022-05-15 |website=Philipps-Universität Marburg |language=de}}</ref>
* 2022: Honorary doctorate from the [[University of Amsterdam|Universiteit van Amsterdam]] (together with Özlem Türeci)<ref>{{Cite web |title=UvA honorary doctorates for vaccine developers Ugur Sahin and Özlem Türeci |url=https://www.eurekalert.org/news-releases/935945 |access-date=2022-05-15 |website=EurekAlert! |language=en}}</ref>
* 2022: [[Louis-Jeantet Prize for Medicine|Louis-Jeantet Prize]] (together with Özlem Türeci and Katalin Karikó)<ref>{{Cite web |last= |date=2021-11-29 |title=Uğur ŞAHIN, Özlem TÜRECI and Katalin KARIKÓ {{!}} Jeantet |url=https://www.jeantet.ch/en/prix-louis-jeantet/laureats/2022-en/ugur-sahin-ozlem-tureci-and-katalin-kariko/ |access-date=2022-05-15 |language=en-US}}</ref>
* 2022: [[Werner von Siemens Ring|Werner-von-Siemens-Ring]] (together with Özlem Türeci, Katalin Karikó, and Christoph Huber)
* 2022: Order of Merit of the State of Rhineland-Palatinate (together with Özlem Türeci)<ref>{{Cite web |last= |first= |last2= |first2= |title=BioNTech-Gründer mit Landesverdienstorden geehrt |trans-title=BioNTech founder honored with State Order of Merit |url=https://www.swr.de/swraktuell/rheinland-pfalz/verdienstorden-land-biontech-gruender-100.html |access-date=2022-05-15 |website=SWR Aktuell |date= 26 January 2022|language=de}}</ref>
* 2022: Ring of Honor of the University Medicine Mainz (together with Özlem Türeci)<ref>{{Cite web |title=Özlem Türeci und Uğur Şahin mit dem Ehrenring der Universitätsmedizin Mainz gewürdigt |trans-title=Özlem Türeci and Uğur Şahin honored with the Ring of Honor of Mainz University Medicine |url=https://idw-online.de/en/news787899 |access-date=2022-05-15 |website=idw-online.de |language=de}}</ref>
* 2022: [[Honorary citizenship]] of Mainz (together with Özlem Türeci) <ref>{{Cite web |title=Ehrenbürger:innenwürde (Aufzeichnung) |url=https://www.mainz.de/kultur-und-wissenschaft/stadtgeschichte/ehrenbuergerwuerde-huber-tuereci-sahin.php |access-date=2022-05-15 |website=mainz.de |language=de}}</ref><ref>{{Cite web |last= |first= |last2= |first2= |date=2022-03-10 |title=Biontech-Gründer sind Mainzer Ehrenbürger |trans-title=Biontech founders are honorary citizens of Mainz |url=https://www.swr.de/swraktuell/rheinland-pfalz/mainz/ehrenbuergerwuerde-mainz-fuer-biontech-gruender-sahin-tuereci-huber-100.html |access-date=2022-05-15 |website=SWR Aktuell |language=de}}</ref>
* 2022: Novo Nordisk Prize<ref>{{Cite web |title=Four scientists receive the Novo Nordisk Prize for their combined contributions to COVID-19 mRNA vaccine |url=https://novonordiskfonden.dk/en/news/four-scientists-receive-the-novo-nordisk-prize-for-their-combined-contributions-to-covid-19-mrna-vaccine/ |access-date=2022-05-15 |website=Novo Nordisk Fonden |language=en-US}}</ref>
* 2022: [[Warren Alpert Foundation Prize]]<ref>{{Cite web |title=Prize Recipients {{!}} Warren Alpert Foundation Prize |url=https://warrenalpert.org/prize-recipients |access-date=2022-05-15 |website=warrenalpert.org}}</ref>

== References ==
{{مصادر|refs=<ref name="bi1">{{Cite news |url=https://www.businessinsider.de/karriere/corona-impfung-ugur-sahin-und-oezlem-tuereci-haben-ihn-entwickelt/ |newspaper=[[Business Insider]] |title=Von Gastarbeiter-Kindern zu Milliardären: Biontech-Chef Ugur Sahin und seine Frau Özlem Türeci gehören zu den 100 reichsten Deutschen |author=Rudnick, Hendrikje |date=11 November 2020 |language=de |access-date=15 November 2020 }}</ref>}}

== External links ==
{{Scholia|author}}
{{تصنيف كومونز|Uğur Şahin}}
* [https://biontech.de/our-dna/leadership Leadership team] of BioNTech SE
* {{Google Scholar id|MzVQ-OMAAAAJ}}

{{Princess of Asturias Award for Technical and Scientific Research}}
{{Authority control}}

{{DEFAULTSORT:Şahin, Uğur}}
[[تصنيف:1965 births]]
[[تصنيف:Living people]]
[[تصنيف:Saarland University alumni]]
[[تصنيف:University of Cologne alumni]]
[[تصنيف:Academic staff of Johannes Gutenberg University Mainz]]
[[تصنيف:German billionaires]]
[[تصنيف:German chief executives]]
[[تصنيف:German immunologists]]
[[تصنيف:German oncologists]]
[[تصنيف:Naturalized citizens of Germany]]
[[تصنيف:21st-century Turkish physicians]]
[[تصنيف:Turkish emigrants to West Germany]]
[[تصنيف:Turkish billionaires]]
[[تصنيف:Turkish chief executives]]
[[تصنيف:BioNTech]]
[[تصنيف:Knights Commander of the Order of Merit of the Federal Republic of Germany]]
[[تصنيف:Members of the European Molecular Biology Organization]]
[[تصنيف:People from İskenderun]]
[[تصنيف:21st-century German businesspeople]]
[[تصنيف:21st-century German physicians]]
[[تصنيف:21st-century Turkish businesspeople]]
[[تصنيف:Physician-scientists]]
[[تصنيف:COVID-19 researchers]]

نسخة دلوقتى 18:46، 2 اكتوبر 2023

تحويل ل:

اتجابت من "https://arz.wikipedia.org/w/index.php?title=Uğur_Şahin&oldid=8284977"